COX-2 inhibitor use in the Women's Health Initiative trials: re-analysis of the data

  • Published 2007 in Nature Clinical Practice Rheumatology


MM-093 significantly improved the mean disease activity score (DAS) 28 and the mean patient’s global assessment compared with placebo. A moderate response in the DAS28 score at week 12 was observed in 4 of the patients receiving MM-093, compared with none in the placebo group. Treatmentemergent adverse events were reported by 11 of the patients, but no… (More)
DOI: 10.1038/ncprheum0567